Compare cybersecurity audit quotes in Boston
Boston's economy is shaped by life sciences, healthcare, and higher education - three sectors with some of the most demanding cybersecurity compliance requirements in the US. HIPAA governs healthcare data; FDA 21 CFR Part 11 governs electronic records in pharmaceutical and biotech companies; and the SEC's 2023 cybersecurity disclosure rules impose specific obligations on public companies. Massachusetts also has among the most prescriptive state-level data security regulations in the country - 201 CMR 17.00 requires a written information security program (WISP) for any business holding Massachusetts residents' personal data. Security firms in Boston range from life sciences specialists to large practices. RFXapp lets you collect structured quotes and compare exactly what each firm tests and certifies.
If you are looking for the best security firms in Boston, the most reliable shortlist is one built around your own requirements and tested with a structured brief - not a generic ranked list. RFXapp helps you find and collect quotes from the right suppliers, and analyze them so you can compare what they actually offer, not just the headline price.
What to consider before you go to market
Getting comparable quotes starts with a well-scoped brief. These are the things most businesses overlook until they're already in the process.
HIPAA security risk assessment: mandatory and heavily enforced
Boston's dense healthcare and life sciences sector makes HIPAA one of the most common compliance drivers for cybersecurity audits. HIPAA requires covered entities and business associates to conduct regular security risk assessments following NIST SP 800-30 or equivalent methodology, covering all PHI regardless of format. HHS OCR enforces HIPAA and has levied multi-million dollar fines against Massachusetts healthcare organizations. A HIPAA risk assessment is not a penetration test - it is a systematic analysis of risks to PHI confidentiality, integrity, and availability, producing a risk register with documented remediation. A security firm working in Boston's healthcare sector must understand this methodology specifically, not just general cybersecurity audit practice.
FDA 21 CFR Part 11: electronic records security for pharma and biotech
For Boston's pharmaceutical and biotech companies, FDA 21 CFR Part 11 governs electronic records and electronic signatures used in FDA-regulated activities - clinical trial data, manufacturing records, laboratory data, and regulatory submissions. Part 11 requires audit trails, access controls, and validation of software systems used for regulated records. A cybersecurity audit for a pharma or biotech company must address Part 11 controls for regulated systems - not just general IT security. FDA inspections increasingly scrutinize data integrity and electronic records security. A security firm that cannot discuss Part 11 requirements is not suited for Boston life sciences clients.
Massachusetts 201 CMR 17.00: written information security program required
Massachusetts has one of the most prescriptive state data security regulations in the US. 201 CMR 17.00 requires any business that owns or licenses personal information about Massachusetts residents to maintain a comprehensive Written Information Security Program (WISP). The WISP must cover employee training, third-party vendor oversight, physical security, and technical controls including encryption of personal information on laptops, portable devices, and in transit. The Massachusetts Attorney General has brought enforcement actions under this regulation. A cybersecurity audit should assess your WISP for completeness and identify gaps that create enforcement exposure.
SEC cybersecurity disclosure rules (2023): obligations for public companies
The SEC's December 2023 cybersecurity disclosure rules require public companies to disclose material cybersecurity incidents within four business days of determining materiality, and to make annual disclosures about their cybersecurity risk management, strategy, and governance. For Boston public companies in biotech, MedTech, and technology, these rules mean the board and audit committee need to be informed about cybersecurity posture and incident risk. A cybersecurity audit firm working with public company clients in Boston should be able to structure their findings for SEC disclosure purposes and advise on what constitutes a material cybersecurity risk for disclosure.
SOC 2 Type II: required by institutional investors and enterprise clients
Boston biotech and technology companies raising institutional capital or selling to enterprise clients increasingly need SOC 2 Type II reports. SOC 2 Type II is a third-party attestation of controls over a 6-to-12-month period, conducted by a licensed CPA firm. A penetration test is supporting technical evidence for your SOC 2 - not a substitute for the formal audit. A SOC 2 readiness assessment identifies control gaps before the audit period begins. Know whether you need a readiness assessment, a penetration test, or both, and confirm the security firm you engage understands these as distinct services.
Tester credentials: OSCP, GPEN, and GWAPT as the industry benchmark
The most credible individual credentials for penetration testers are OSCP (a 24-hour practical exam), GPEN and GWAPT (GIAC network and web application testing certifications), and CHFI for forensics. Boston institutional clients in healthcare and life sciences are increasingly sophisticated about asking for individual tester credentials rather than accepting firm-level certifications. Ask for the specific certifications held by the named tester who will lead your engagement - particularly for HIPAA-covered engagements where HHS OCR may review the tester's qualifications in an investigation.
Hidden costs and oversights that catch Boston businesses out
These are the items that make two cybersecurity audit quotes look comparable on paper but leave your HIPAA risk assessment incomplete or your FDA electronic records compliance at risk.
HIPAA risk assessments that cover only electronic systems and miss paper and portable media
HHS OCR enforcement findings consistently identify inadequate risk assessment scope as the most common HIPAA compliance failure. Specifically, risk assessments that cover only electronic PHI and miss paper records, portable media (USB drives, external hard drives), and PHI transmitted verbally are incomplete under the regulation. In Boston's research hospital and academic medical center environment, PHI often exists across multiple formats and systems. A security firm that conducts a network penetration test and calls it a HIPAA risk assessment is producing a deliverable that will not withstand OCR scrutiny. Verify that the firm's HIPAA methodology covers all PHI formats explicitly.
FDA 21 CFR Part 11 systems excluded from standard audit scope
Biotech and pharma companies typically run separate validated systems for regulated activities (LIMS, EDC systems for clinical trial data, ERP for manufacturing records) that are distinct from their general IT infrastructure. Standard penetration test scopes frequently exclude these systems because they are "validated" and testers are concerned about disruption. But a security audit that excludes the systems holding your most sensitive and regulated data - clinical trial data, manufacturing records, regulatory submission data - is missing the highest-value target for a sophisticated attacker. Work with the security firm to define a methodology for assessing Part 11 system security without disrupting validation status.
No retest included: paying full rates while under investor or regulatory pressure
For Boston biotech companies in investor due diligence or preparing for an FDA inspection, a penetration test with no pre-agreed retest policy creates specific commercial risk. Findings are delivered, you begin remediating, and then you need a closed retest to demonstrate to your investor or FDA readiness reviewer that vulnerabilities are addressed - but the retest is priced at full rate after findings are known. On a five-day pentest at $18,000-$35,000, a retest for critical findings adds $6,000-$14,000 if not pre-agreed. Negotiate retest terms - scope, timing, and price - before signing the initial engagement.
Questions that separate good security firms from great ones
Asking is only half the job. Below each question is what a good answer sounds like, and what should give you pause. Questions marked * are mainly relevant for larger or more complex engagements - for a straightforward vulnerability assessment you can skip those.
Good answer: They reference NIST SP 800-30 or HHS OCR's published risk assessment guidance explicitly, describe coverage of all PHI formats, and provide a client reference in the healthcare or life sciences sector whose OCR documentation they have supported. They understand the distinction between a HIPAA risk assessment and a penetration test.
Red flag: "We have healthcare experience" without referencing NIST SP 800-30 or HHS OCR methodology. Or conflating the HIPAA risk assessment with a penetration test - they are distinct services requiring different methodologies.
Good answer: They describe their methodology for assessing validated systems - typically a combination of configuration review, access control testing, and audit trail integrity verification - without invasive testing that would trigger revalidation. They may reference GAMP 5 or FDA Computer Software Assurance guidance in their approach.
Red flag: "We do not test validated systems due to compliance risk." That is a refusal to engage with a real and significant attack surface. Or, conversely, proposing to test Part 11 systems using standard penetration testing methodology without discussing validation preservation - which shows they do not understand the regulatory constraint.
Good answer: They confirm knowledge of 201 CMR 17.00, describe the specific requirements they assess (employee training, third-party oversight, encryption of personal data in transit and on portable devices), and can distinguish a WISP compliance review from a technical penetration test as complementary services.
Red flag: No knowledge of 201 CMR 17.00 or treating it as equivalent to HIPAA or general privacy law. It is a specific Massachusetts state regulation with distinct requirements, and a firm working in Boston should know it by name.
Good answer: They name a specific tester, confirm their certifications, and can explain which credentials apply to your scope type. They are comfortable providing documentation.
Red flag: "Our team is highly qualified." Company-level statements tell you nothing about who will run your specific test.
Good answer: A specific policy: one retest of all critical and high findings within 90 days, included in the base price, or a fixed pre-agreed day rate. Terms established before the initial test.
Red flag: "We will discuss retest options after the report." Maximum leverage for the firm at minimum leverage for you.
Good answer: They describe how they translate technical findings into board-level risk language, reference the SEC's 2023 disclosure rule and its materiality concept, and can help the audit committee or CISO structure findings for annual Form 10-K cybersecurity disclosures. They understand that materiality in the SEC sense combines likelihood and magnitude of business impact.
Red flag: No knowledge of the 2023 SEC cybersecurity disclosure rules. For a firm working with public companies in Boston's biotech and technology sector, this is a basic expectation.
Where you have more negotiating room than you think
Security firms have more flexibility on price and terms than they lead with. These are the levers that actually work once you have competing quotes in front of you.
Bundle HIPAA risk assessment with penetration testing and 201 CMR 17.00 WISP review
Boston healthcare and life sciences companies typically need all three: a HIPAA risk assessment, a penetration test, and a Massachusetts WISP compliance review. Commissioning all three in a single integrated engagement removes the firm's cost of three separate acquisition and ramp-up processes and typically produces 15-25% savings. The services also inform each other - technical findings from the penetration test feed into risk ratings in the HIPAA assessment, and the WISP review can be scoped around the same data assets. For Boston firms managing multiple compliance calendars, integration also reduces elapsed time.
Pre-agree retest scope and price before the initial engagement
Once findings are delivered, firms with retest services have maximum leverage. Pre-agreeing terms removes this entirely. For Boston biotech companies in investor due diligence or FDA preparation, a pre-agreed retest also gives you a timeline you can communicate to your investor or FDA readiness reviewer before the test starts - which is often the commitment they need to proceed.
Competitive quotes from three qualified firms on an identical scope
Boston has a substantial pool of security firms with life sciences and healthcare experience, but pricing varies significantly - day rates range from $1,500 to $3,000 for comparable qualifications. Running a structured RFQ with two or three firms on the same defined scope creates real competitive tension. Firms that know they are competing sharpen proposals in ways they will not in a sole-source conversation.
Annual retainer for HIPAA-compliant security program management
HIPAA requires regular risk assessments - not necessarily annual, but OCR expects a documented cadence. An annual retainer covering a HIPAA risk assessment, biannual vulnerability assessments, and one penetration test gives the security firm predictable revenue they will price competitively. A retainer worth $40,000-$70,000 per year for a Boston life sciences company consistently produces better terms than individual engagements of equivalent total value.
Phase the test: general infrastructure first, regulated systems second
For Boston biotech and pharma companies, phasing the engagement - general IT infrastructure and web application test first, regulated (Part 11) systems second - lets you assess the firm's capability and methodology before exposing them to your validated systems. Phase 2 for validated systems can be structured as a configuration and access control review rather than an active exploitation test, which reduces validation risk while still producing a meaningful security assessment.
Timing: avoid Q4 and JPMorgan Healthcare Conference season in January
Boston security firms are busiest in Q4 as companies close annual compliance requirements, and in January when life sciences companies are simultaneously managing investor conference preparation and year-start compliance planning. Testing in Q2 or Q3 produces better tester availability and occasionally a pricing concession. For biotech companies with investor due diligence timelines, building a six-to-eight week buffer from test start to closed retest is important for any fundraising timeline.
From "I need a cybersecurity audit" to signed off and compliant
Describe what you need
Write your requirements in your own words - scope, location, timeline, any constraints. RFXapp turns it into a structured brief and prompts you for anything that will help security firms quote accurately.
Invite your security firms
Add the security firms you've already shortlisted, or let RFXapp find local options. They reply by normal email - no portal, no registration.
Compare quotes side by side
RFXapp reads every response and standardises the quotes into a side-by-side view - inclusions, exclusions, assumptions and all.
Negotiate and appoint
RFXapp drafts targeted negotiation emails based on the gaps between quotes. You review and send. Then award the contract from your dashboard.
Other things Boston businesses source on RFXapp
Most of our users run 5-10 separate buying projects a year. This is often how they find us, but it's rarely the last thing they use us for.